The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus (OVV) comprising one of more of a) a nucleotide sequence encoding a variant A33 polypeptide, b) a nucleotide sequence encoding a variant A34 polypeptide, and c) a nucleotide sequence encoding a variant B5 polypeptide, wherein the variant A33, variant A34, and variant B5 polypeptides comprise one or more amino acid substitutions that provide for enhanced virus spreading or enhanced EEV production as compared with a virus encoding a corresponding wild-type A33, A 34, and B5 polypeptide. The present disclosure also provides compositions comprising the OVV and use of the OVV or the composition for inducing oncolysis in an individual having a tumor.

The disclosure relates to methods and materials for treating cancer. For example, recombinant vaccinia viruses having the ability to direct the expression of membrane-bound IL-12 polypeptides on the surface of infected cells and methods for using such recombinant vaccinia viruses to treat cancer are provided. Specifically, the disclosure provides a recombinant vaccinia virus comprising a vaccinia virus genome comprising a nucleic acid encoding an IL-12p35 polypeptide sequence and an IL-12p40 polypeptide sequence, wherein one of the polypeptide sequences comprises a membrane anchoring polypeptide sequence.

The disclosure relates to modified vaccinia virus vectors derived from the Copenhagen strain of vaccinia virus, as well as methods of using the same for the treatment of various cancers. The disclosure provides modified Copenhagen-derived vaccinia virus vectors that exhibit various beneficial therapeutic activities, including enhanced oncolytic activity, spread of infection, immune evasion, tumor persistence, capacity for incorporation of exogenous DNA sequences, amenability for large scale manufacturing, and safety.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.

Clonal strains of vaccinia viruses are provided. Also provided are methods of identifying and isolating attenuated and oncolytic clonal strains from virus preparations. Modified recombinant forms of the clonal strains also are provided. The clonal strains and virus preparations can be used for diagnostic and therapeutic methods, in particular for therapy and diagnosis or monitoring treatment of proliferative disorders, including neoplastic diseases, such as, but are not limited to, solid tumors and blood cancers.

The present disclosure provides a replication-competent, recombinant oncolytic vaccinia virus; and compositions comprising the replication-competent, recombinant oncolytic vaccinia virus. The present disclosure also provides use of the vaccinia virus or composition for inducing oncolysis in an individual having a tumor.

The present invention relates to a tumor-targeting protein or a fragment thereof, an antibody binding thereto and a use thereof. More specifically, the present invention relates to a vector containing a nucleic acid coding for the protein A56 or a fragment thereof, and a use thereof. In addition, the present invention relates to an antibody binding to the protein A56 or a fragment thereof, and a use thereof. The vector containing the nucleic acid coding for the protein A56, a fragment thereof or a mutant thereof of the present invention uses an oncolytic virus as the vector, and thus, when administered in an individual, specifically kills only cancer cells, primarily. In addition, cancer cells which have survived even after being infected with the oncolytic virus express the protein A56 on the cell surfaces thereof, and thus may be targeted for secondary anticancer therapy. Thus, cancer may be effectively treated when the vector containing the nucleic acid coding for the protein A56 or a fragment thereof, and the antibody binding to A56, according to one embodiment of the present invention, are used.

Recombinant oncolytic viruses for expression of sialidase and their use in the treatment of cancer, particularly solid tumors, are described.

Provided herein are carrier cells and virus combinations and methods for treatment of cancers. Also provided are modified carrier cells for such treatment, and methods of selecting carrier cells that are matched to subjects for such treatment.

The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.